This is a multi-center, single-arm, open-label phase 3 study to evaluate the safety, efficacy, Pharmacokinetics(PK) and immunogenicity of Stapokibatrt in children with Atopic Dermatitis.
Eligibility
Sex
ALL
Min age
2 Years
Max age
12 Years
Healthy volunteers
No
Inclusion Criteria:
* Voluntarily participate in the continuing study and sign the written Informed Consent Form(ICF).
* Subjects who must complete the evaluation of Week 18 of the main study.
* Have the ability to communicate well with the researcher and comply with the follow-up visits of the protocol.
Exclusion Criteria:
* Planned major surgical procedure during the patient's participation in this study.
* Any other circumstances in which the researcher deems not suitable to participate in this study.
Primary outcome measure(s)
Adverse events — up to week 44 Incidence of adverse events
Trial sites (1)
Facility
City
Region
Status
Beijing Children's Hospital Capital Medical University
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.